Molecular Signatures of Cutaneous Squamous Cell Carcinoma During Recessive Dystrophic Epidermolysis Bullosa
NCT ID: NCT04285294
Last Updated: 2020-02-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
66 participants
OBSERVATIONAL
2020-03-31
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The objective of the study is to describe the molecular signatures in the cSCC in RDEB patients
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Artificial Intelligence Patient App for RDEB SCCs
NCT05843994
Study of the Blood and Skin Immunological Profile of Patients With Recessive Dystrophic Epidermolysis Bullosa: in Vivo Analysis and the Impact of Placental Stem Cells in Vitro
NCT06177353
Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa
NCT01019148
Rigosertib for RDEB-SCC
NCT03786237
Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa
NCT00904163
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RDEB patients with a cSCC
No interventions assigned to this group
Non-RDEB patients with a SCC induced by ultraviolet radiation
No interventions assigned to this group
Healthy donors without RDEB nor SCC
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. aged older than 18 years old
2. one or more SCC surgically treated
3. signed genetic consent form
* for non-RDEB patients with a SCC induced by ultraviolet radiation :
1. aged older than 18 years old
2. one or more SCC induced by ultraviolet radiation
3. signed genetic consent form
Exclusion Criteria
* without health insurance coverage
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APHP190820
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.